Sign In
Media & Investors
Skip Navigation LinksSanten > EMEA > Media & Investors > News > Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.
Contact
Santen Pharmaceutical welcomes your inquiries and opinions.

Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.

4/4/2014
​April 4, 2014, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (Osaka, Japan, hereinafter referred to as "Santen") signed a licensing agreement (“Agreement”) with Oak Pharmaceuticals, Inc. (Lake Forest, Illinois, U.S., “Oak Pharmaceuticals”), a subsidiary of Akorn, Inc. ("Akorn") pertaining to the sales and marketing in the United States of tafluprost, the treatment of glaucoma and elevated intraocular pressure. Tafluprost is trademarked as ZIOPTAN® in the U.S. and TAPROS in Japan. Oak Pharmaceuticals recently acquired tafluprost business from Merck & Co., Inc. (New Jersey, U.S., "Merck") and has been granted the rights to sell and market tafluprost in the U.S. by Santen pursuant to the ​Agreement.

 

Marketed in more than 60 countries, tafluprost is a prostaglandin analogue Santen co-developed with Asahi Glass Co., Ltd.Tokyo, Japanfor the treatment of glaucoma and elevated intraocular pressure. In April 2009, Santen granted the U.S. licensing rights for tafluprost to Merck.

 

Under the Agreement, Santen has certain rights to receive royalties on sales of ZIOPTAN® from Oak Pharmaceuticals. The Agreement is not expected to have a significant impact on Santen's consolidated financial performance for the fiscal year ended March 31, 2014.

About Santen

Founded in 1890, Santen is a global company headquartered in Osaka, Japan. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide. Tokyo Stock Exchange code 4536. For more information, visit www.santen.com.

About Akorn and Oak Pharmaceuticals

Akorn is a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois, Somerset, New Jersey and Paonta Sahib, India where the Company manufactures ophthalmic and injectable pharmaceuticals. Additional information is available on the Company’s website at www.akorn.com. Akorn’s wholly-owned subsidiary, Oak Pharmaceuticals, is engaged in the sales and marketing of branded drugs.​

Note on Forward-looking Statements for Santen

Information provided in this press release contains so-called “forward-looking statements”. The realization of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by governments in Japan and other nations concerning medical insurance, drug pricing and other systems, as well as fluctuations in market variables such as interest and foreign exchange rates.

Contact information

Geneviève Garrigos

Director, Corporate Communication Europe

Tel: + 33 6 65 54 60 19

genevieve.garrigos[at]santen.fr